OTCMKTS:SLNCF Silence Therapeutics (SLNCF) Stock Price, News & Analysis → What is the 72-Hour Profit Surge? (From DTI) (Ad) Free SLNCF Stock Alerts $8.00 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$8.00▼$8.0050-Day Range$2.50▼$9.0052-Week Range$0.60▼$10.90VolumeN/AAverage Volume1,315 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Silence Therapeutics alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Silence Therapeutics Stock (OTCMKTS:SLNCF)Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.Read More SLNCF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLNCF Stock News HeadlinesApril 23, 2024 | msn.comRadio Silence teases bombshell Abigail-Ready or Not connectionApril 16, 2024 | msn.comMovie review: Radio Silence brings maximalist style to vampire flick 'Abigail'April 25, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 16, 2024 | msn.comChinese Pop Idol Silence Wang’s Career Under Fire Amidst Sexual Harassment ClaimsApril 9, 2024 | msn.comColorado Springs Cycling Club honors fallen cyclists with “Ride Of Silence” eventApril 9, 2024 | msn.comQuiet on Set: Breaking the Silence Doesn't Let Dan Schneider Have the Last WordApril 4, 2024 | usnews.comDescendants of Enslaved, Enslavers 'Break Silence' Around France's PastApril 3, 2024 | msn.comManoj Bajpayee, Prachi Desai on mission to solve shootout in 'Silence 2'April 25, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 31, 2024 | msn.comScream: Radio Silence Discusses Leaving the FranchiseMarch 29, 2024 | msn.comReady or Not 2 gets update with disappointing Radio Silence twistMarch 26, 2024 | msn.comSilence S04 reviewMarch 18, 2024 | news.yahoo.comCalifornia prison guard sentenced in ‘Code of Silence’ cover-up involving inmate deathMarch 18, 2024 | nytimes.comThe Unforgivable Silence on SudanMarch 14, 2024 | markets.businessinsider.comBullish on Silence Therapeutics: Buy Rating Affirmed Amid Strong Phase 2 Results for ZerlasiranMarch 14, 2024 | markets.businessinsider.comThese Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 ResultsMarch 14, 2024 | finance.yahoo.comSilence Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 13, 2024 | msn.comOff the Grid: Sally breaks down USA TODAY's daily crossword puzzle, Break the SilenceMarch 12, 2024 | msn.comBali marks New Year with annual Day of SilenceMarch 12, 2024 | markets.businessinsider.comHere's what Wall Street expects from Silence Therapeutics's earnings reportMarch 12, 2024 | angelusnews.com‘Into Great Silence’ and faith lived loudlyMarch 11, 2024 | msn.comAre We Witnessing The ‘Silence’ Of College Football?February 18, 2024 | usnews.comG7 Foreign Ministers Observe a Minute's Silence for NavalnyFebruary 18, 2024 | msn.com‘Maria's Silence' Director Talks Showbiz Pals of Dictators: "They Know How to Pretend"February 5, 2024 | msn.comShouts, Not Silence on Border Question – On This Day in 1924January 31, 2024 | usnews.comKentucky House Committee Passes Bill Requiring Moment of Silence in SchoolsJanuary 24, 2024 | yahoo.com"It's a huge risk": exploring the Art Nouveau style of video game Songs of SilenceSee More Headlines Receive SLNCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:SLNCF CUSIPN/A CIK1479615 Webwww.silence-therapeutics.com Phone442034576900FaxN/AEmployees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Craig A. Tooman M.B.A. (Age 59)President, CEO & Executive Director Comp: $1.46MMs. Rhonda L. Hellums (Age 51)CFO & Secretary Comp: $890.6kDr. Steven J. Romano M.D. (Age 65)Head of Research & Development Comp: $650.51kDr. Marie Wikstrom Lindholm Ph.D.Chief Scientific OfficerMs. Gem Gokmen HopkinsHead of IR & Corporate CommunicationsDr. Barbara A. Ruskin J.D. (Age 63)Ph.D., Senior VP and Chief Intellectual Property & Innovation Officer Dr. Eric Floyd M.B.A. (Age 61)M.S., Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance Mr. J.P. GabrielChief Technical Operations OfficerMr. Curtis Rambaran M.D.Chief Medical OfficerMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors SLNCF Stock Analysis - Frequently Asked Questions How have SLNCF shares performed in 2024? Silence Therapeutics' stock was trading at $1.50 at the start of the year. Since then, SLNCF stock has increased by 433.3% and is now trading at $8.00. View the best growth stocks for 2024 here. How do I buy shares of Silence Therapeutics? Shares of SLNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SLNCF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
